


# Stability testing

Aulton  
Chapter 7




## Specification, stability, inprocess controls and validation




# What are stability investigations?

All medicinal products decompose over time. Stability testing investigates this decomposition




## When and why?



- Pre-formulation
  - Investigating the stability of the drug substance
- Development
  - Ensuring stability during tox and clinical tests
  - Drug optimisation
  - Determinating the shelf-life and conducting formal studies for the filling of the product
- Changes in the product or production
  - Ensuring that the quality of the product is unaffected



## Accelerated testing



### Why

- To obtain information faster
- To obtain information to cover transport and storage conditions (refrigerated products)

### How


- Store samples at higher temperatures or humidity levels

### Problems

- Low predictability if the reaction pattern is different at high temperatures and humidity levels.



## Light tests



### Why

- To obtain information on photo-degradation for choice of packaging

### How


- Test one batch during development and employ one confirmatory test
- Expose the sample to artificial daylight at normal storage temperature
- The exposure time selected should be justified

### Problems

- How to avoid heating the sample during testing



# Freeze-thaw tests



## Why

- To ensure that freezing does not alter the sample, for example due to crystallisation
- Important for ensuring transport stability

## How

- Let the sample go through a number of freeze thaw cycles.

## Problems

- No standard procedures available



# ICH Guidelines

- Q1A(R2); Stability Testing of New Drug Substances and Products
- Q1B; Stability Testing : Photostability Testing of New Drug Substances and Products
- Q1C; Stability Testing for New Dosage Forms
- Q1D; Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products
- Q1E Evaluation of Stability Data
- Q1F: Stability Data Package for Registration Applications in Climatic Zones III and IV



## ICH Guidelines what to test


- **Test conditions**
  - Long term
  - Accelerated
  - Photostability testing should be conducted on at least one primary batch of the drug product if appropriate.
  - Freeze stability
- **To tests for**
  - Chemical stability
    - Content (>95 of label)
    - Total impurities (<5%)
    - Known impurities
    - Unknown (<0,1%-1%)
    - Uniformity of content
  - Physical
    - Dissolution
    - Particle size
    - Hardness (tablets)
  - Microbiological integrity



## limits for impurities

- **Reporting limits**
  - Daily dose <1mg , 0,1%
  - Daily dose <1 mg , 0,05%
- **Identification threshold: a limit above (>) which a degradation product should be identified**

Maximum Daily Dose <sup>1</sup>	Threshold (what ever comes first)
< 1 mg	1.0% or 5 g TDI
1 mg - 10 mg	0.5% or 20 g TDI
>10 mg - 2 g	0.2% or 2 mg TD
> 2 g	0.10%



## Special consideration for biotechnology products

- Assays of biological activity should be part of the pivotal stability studies.
- Physical chemical characterisation, immune assays, etc. should be included
- Where possible, batches of the final container product included in stability testing should be derived from different batches of bulk material.
- the expiration dating should be based on real-time/real-temperature data.



## Formal stability testing

### Product tested

- The final product in its primary package.

### Batches tested

- At least 3
- At least 2 batches of 3 produced in a pilot scale
- The 3 first production batches should always be placed on stability

### Analytical methods

- Validated

### Test conditions

- Normal storage temperature
- (Intermediate)
- Accelerated

### Test frequency

- Year 1: 3 month intervals
- Year 2: 6 month intervals
- Year ≥ 3: yearly

### Test duration

- Long term: 12 months beyond shelf life, no less than 12 months
- Accelerated and intermediate: 6 months



# Special issues concerning bio-molecules

- **Stability**

- On the whole, there is no single stability-indicating assay or parameter that profiles the stability, the manufacturer should propose a stability-indicating profile that provides assurance that changes in the identity, purity, and potency of the product will be detected
- Assays for biological activity, where applicable, should be part of the pivotal stability studies.
- For the purpose of stability testing, tests for purity should focus on methods for determination of degradation products.



## Test temperatures

- **Storage at room temperature**

	Study Storage condition
Long-term	25°C ± 2°C/60% RH ± 5% RH or 30°C ± 2°C/65% RH ± 5% RH
Intermediate	30°C ± 2°C/65% RH ± 5% RH
Accelerated	40°C ± 2°C/75% RH ± 5% RH


- **Refrigerated storage**

	Study Storage condition
Long-term	5°C ± 3°C
Accelerated	25°C ± 2°C/60% RH ± 5% RH

- For drug products intended for storage in a freezer, the shelf life should be based on the real time data obtained at the long-term storage condition.



## The prediction of shelf life



- Determine the test parameters that change over time
- Determine when 95% of a one sided confidence interval intersect the specification limits
- If batches are similar, the data from all batches can be pooled.
- In other cases, shelf life is determined by the worst case
- Note that not all changes are linear.



## Kinetic of chemical degradation

The reaction rate is often dependent upon the concentration of reactants

$$\frac{dC}{dt} \propto f(C) \quad \text{c.} \quad \frac{1}{f(C)} = kt$$

➤ **Zero order**



$$f(C) = k$$

➤ **First order**

$$f(C) = kC$$

➤ **Second order**

$$f(C) = kC^2 \quad f(C) = kC_a C_b$$





## Arrhenius equation


$$k = A * e^{-E_a / RT}$$

### Use

- To evaluate the degradation constant from accelerated data

### Risk

- Incorrect for complex degradation profiles



## Evaluation in reality



- Most parameters are found to be not shelf life determining simply by looking on the results
- If there is no strong evidence against it, zero order kinetics is assumed
- The shelf life is not always investigated in follow up stability investigations



## When to test existing products

When there is a risk that a change could affect the drug product

- A change in the excipients
- A change in the primary packing material
- A change in the manufacturing process
- An increased in the batch size

Annual tests of every sold product (US requirements)

- Package of all sizes
- Only at the prescribed storage temperature
- Failure: Authorities have to be notified and the product be withdrawn from the market



## How to reduce the amount of work required

### Matrixing

To reduce the number of samples analysed at any given time. Have to show that the predictability of the model works.

Time	A	B	C	D
3	x	x	x	x
6	-	x	-	x
9	x	-	x	-
12	-	x	-	x
24	x	x	x	x

### Bracketing

To investigate only the extremes and assume a linear behaviour of parameters in between.

#### Example

Only investigate the smallest and the largest pack size for an oral formulation.



## **Terms to know from today's lecture**

- **Shelf-life** the time during which the product is safe to use
- **Formal stability study.** a stability study used to determinate shelf-life
- **Matrixing and Bracketing** ways of reducing the amount of work during a stability study
- **ICH International Committee of Harmonisation** (Common guidelines for Japan, the US and Europe)



## **Seminar stability investigation**



## **Design a stability study**

- In groups of four discuss what should be included in a design of a stability study
- Individually design the study for the formulation you have obtained
- Present your design for the other member of your group and discuss in the group each others studies.



## **Estimation of stability**

- In group of four discuss how to calculate the shelf-life for the formulations
- Calculate shelf-life for one of the three disintegrant
- Discuss in what way this study does differ from a formal study.

